Analysis of thrombophilic genetic mutations in patients with Sheehan's syndrome: Is thrombophilia responsible for the pathogenesis of Sheehan's syndrome?

Pituitary

Volumn 14, Issue 2, 2011, Pages 168-173

  Gokalp, Deniz ^a   Tuzcu, Alpaslan ^a   Bahceci, Mithat ^a   Ayyildiz, Orhan ^a   Yurt, Murat ^a   Celik, Yusuf ^a   Alpagat, Gulistan ^a  

^a DICLE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Sheehan syndrome; Thrombofilic factors

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 9; CORTICOTROPIN; CYANOCOBALAMIN; ESTRADIOL; FOLIC ACID; FOLLITROPIN; GROWTH HORMONE; HOMOCYSTEINE; HYDROCORTISONE; LIOTHYRONINE; LUTEINIZING HORMONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROLACTIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; THYROTROPIN; THYROXINE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DNA POLYMORPHISM; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HYPOPITUITARISM; PATHOGENESIS; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; THROMBOPHILIA; THROMBOSIS;

ADULT; CASE-CONTROL STUDIES; DNA MUTATIONAL ANALYSIS; FACTOR V; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPOPITUITARISM; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MUTATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTHROMBIN; THROMBOPHILIA;

EID: 79958125205     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-010-0276-x     Document Type: Article

References (33)

1. Sheithauer B, Sano T, Kovacs K, Young W Jr, Ryan N, Randall R (1990) The pituitary gland in pregnancy: a clinicopathologic and immunohistochemical study of 69 patients. Mayo Clin Proc 65(4):461
2. Goswami R, Kochupillai N, Crock P, Jaleel A, Gupta N (2002) Pituitary autoimmunity in patients with Sheehans syndrome. J Clin Endocr Metab 87(9):4137
3. Kelestimur F (2003) Sheehan's syndrome. Pituitary 6:181-188
4. Carp H, Salomon O, Seidman D, Dardik R, Rosenberg N, Inbal A (2002) Prevalence of genetic markers for thrombophilia in recurrent pregnancy loss. Hum Reprod 17:1633-1637 (Pubitemid 34661820)
5. Bick RL, Hoppensteadt D (2005) Recurrent miscarriage syndrome and infertility due to blood coagulation protein/platelet defects: a review and update. Clin App Thromb Hemost 11:1-13 (Pubitemid 40194193)
6. Foka ZJ, Lambropoulos AF, Saravelos H et al (2000) Factor V Leiden and prothrombin G20210A mutations, but not methylenetetrahydrofolate reductase C677T, are associated with recurrent miscarriages. Hum Reprod 15:458-462 (Pubitemid 30076732)
7. den Heijer M, Koster T, Blom HJ et al (1996) Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 334:759-762 (Pubitemid 26089357)
8. Tassies D, Espinosa G, Munoz-Rodriguez FJ et al (2000) The 4G/ 5G polymorphism of the type 1 plasminogen activator inhibitor gene and thrombosis in patients with antiphospholipid syndrome. Arthritis Rheum 43:2349-2358
9. Stegnar M, Uhrin P, Peternel P et al (1998) The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor- 1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism. Thromb Haemost 79:975-979 (Pubitemid 28224735)
10. Sheehan HL (1937) Postpartum necrosis of the anterior pituitary. J Path Bacteriol 45:189-214
11. Veldhuis JD, Hammond JM (1980) Endocrine function after spontaneous infarction of the human pituitary: report, review, and reappraisal. Endocr Rev 1(1):100-107
12. Di Ziegra D, Kletzky DA, Mishell DR (1978) Diagnosis of Sheehan's syndrome using sequental pituitary stimulation tests. Am J Obstet Gynecol 132:348-353
13. Roberts DM (1998) Sheehan's syndrome. Am Fam Physician 244:261-266
14. Gupta D, Gaiha M, Mahajan R, Daga MK (2001) Atypical presentation of sheehan's syndrome without postpartum hemorrhage. J Assoc Physicians India 49:386-387
15. Kovacs K (2003) Sheehan syndrome. Lancet 361:520-522
16. Kalkanli S, Ayyildiz O, Tiftik N, Batun S, Isikdogan A et al (2006) Factor V Leiden mutation in venous thrombosis in southeast Turkey. Angiology 57(2):193-196 (Pubitemid 44438571)
17. Gurgey A, Mesci L (1997) The prevalence of factor V Leiden (1691G → A) mutation in Turkey. Turk J Pediatr 39:313-315 (Pubitemid 127562936)
18. Rosendaal FR, Doggen CJ, Zivelin A, Arruda VR, Aiach M et al (1998) Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 79:706-708 (Pubitemid 28163839)
19. Ayyildiz O, Kalkanli S, Batun S, Aybak M, Isikdogan A, Tiftik N, Bolaman Z, Soker M, Muftuoglu E (2004) Prothrombin G20210A gene mutation with Lightcycler polymerase chain reaction in venous thrombosis and healthy population in the southeast of Turkey. Heart Vessels 19:164-166 (Pubitemid 39149325)
20. Akar N, Misirlioglu M, Akar E, Avci F, Yalcin A (1998) Prothrombin gene 20210 G-A mutations in Turkish population. Am J Hematol 58:249 (Pubitemid 28303561)
21. Castoldi E, Rosing J (2004) Factor V Leiden: a disorder of factor V anticoagulant function. Curr Opin Hematol 11(3):176-181 (Pubitemid 38952006)
22. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM et al (1995) Enhancement by factor V Leiden mutation of risk of deep vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 346:1593-1596 (Pubitemid 26001841)
23. Rosendaal FR, Koster T, Vandenbroucke JP et al (1995) High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 86:4700-4702
24. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM (1996) A common genetic variation in the 30-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88:3698-3703 (Pubitemid 26383091)
25. Wald D, Law M, Morris J (2002) Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Brit Med J 325:1202-1208
26. Quere I, Perneger T, Zittoun J, Bellet H, Gris JC, Daures JP et al (2002) Red blood cell methylfolate and plasma homocysteine as risk factors for venous thromboembolism: a matched case-control study. Lancet 359:747-752 (Pubitemid 34215074)
27. Hainaut P, Jaumotte J, Verhelst D, Wallemacq P, Gala JP, Lavenne E et al (2002) Hyperhomocysteinemia and venous thromboembolism: a risk factor more prevalent in the elderly and in idiopathic cases. Thromb Res 106(2):121-125 (Pubitemid 35245235)
28. Eichinger S, Stumpflen A, Hirschi M, Bialonczyk C, Herkner K, Stain M et al (1998) Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost 80(4): 566-569 (Pubitemid 28479339)
29. van der Put NM, Gabreels F, Stevens EM et al (1998) A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural ltube defects? Am J Hum Genet 62:1044-1051
30. Weisberg I, Tran P, Christensen B et al (1998) A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 64:169-172 (Pubitemid 28453294)
31. den Heijer M, Lewington S, Clarke R (2005) Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. Thromb Haemost 3:292-299
32. Dossenbach-Glaninger A, van Trotsenburg M, Dossenbach M et al (2003) Plasminogen activator inhibitor 1 4G/5G polymorphism and coagulation factor XIII Val34Leu polymorphism: impaired fibrinolysis and early pregnancy loss. Clin Chem 49(7):1081-1086 (Pubitemid 36751094)
33. Segui R, Estelles A, Mira Y et al (2000) PAI-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects. Br J Haematol 111(1):122-128